- The new program will provide constant guidance to physicians that prescribed marijuana for medical use.
- Canopy Growth’s Spectrum Therapeutics already collaborated with the Santé Cannabis clinic to offer this service.
Canada legalized the use of recreational marijuana almost a year ago, but the landscape is still relatively new. Canopy Growth and other producers want to make sure that this momentum isn’t for nothing, as they work to grow networks to serve medical patients. As a result, the company decided to bring more educational initiatives on the process of prescribing cannabis, leading to the free Prescriber Training Program, which is based out of Montreal.
The program is already active at Canopy’s medical wing called Spectrum Therapeutics, in collaboration with the Santé Cannabis clinic / research centre. Dr. Mark Ware, the chief medical officer for Canopy, recently spoke on the partnership, saying:
“A significant issue preventing the consideration of cannabinoid medicine by healthcare professionals is that the topic is not typically included in medical school curriculum. We’ve invested in a range of education initiatives to address this gap in knowledge, and this new program creates an important resource for Québec physicians.”
To fund this initiative, the program has already received an educational grant. The Santé Cannabis clinic will offer courses that show how to develop treatment plans for dosage, using self-guided modules and direct phone support that physicians can access at any time. These developments were the result of a 500% increase in requests for referral information.
Apart from the licensing that Canopy Growth received for a new extraction facility, as well as an agreement for the acquisition of Beckley Canopy Therapeutics, the summer was relatively uneventful. Unfortunately, the uneventful season led to disappointing results in their revenue.
Presently, Canopy is getting ready to launch edible products and vaporizers, though it also recently paired up with Greenlane Holdings Inc for a distribution deal involving US vaporizer products. However, this couldn’t be timed worse. After all, Health Canada has recently been issuing new regulations that cover these types of products, due to the health issues that have arisen in the United States, as well as several deaths.
Canopy’s stock is presently trading at $27.99 per share, as of Monday.